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Terminal and interstitial deletions of 2p25.3 (size < 3 Mb), detected by array-CGH analysis, have been reported in
about 18 patients sharing common clinical features represented by early-onset obesity/ overweightness associated
with intellectual disabilities (ID) and behavioural troubles. This observations led to hypothesize that 2p subtelomeric
deletion should be associated with syndromic obesity and MYT1L became the main candidate gene for ID and
obesity since it is deleted or disrupted in all hitherto published cases.
Here we described a 2p25.3 de novo terminal deletion of 1.9 Mb, of paternal origin, detected by array-CGH analysis
in a girl of 4.4 years with a distinctive phenotype consisting of early-onset of obesity associated with moderate ID,
and hyperkinetic disorder. The deletion disrupted MYT1L and encompassed five other OMIM genes, ACP1, TMEM18,
SNTG2, TPO, and PXDN.
Here, we discuss the combined functional effects of additional haploinsufficient genes, that may concur with
heterozygous deletion of MYT1L, in the aetiology for syndromic obesity associated with 2p25.5 subtelomeric
deletion.
Keywords: Deletion 2p25.3, Obesity, Language delay, Hypekinetic disorder, MYT1LBackground
Monosomies of 2p are very rare and are usually ob-
served in more complex aberrations such as inverted/
duplications [1], ring 2 chromosomes [2-4], or a deriva-
tive chromosome 2 ([5] one case) making a definite cor-
relation between severity of the phenotype and size or
type of the aberrations still difficult.
Recently, terminal and interstitial deletions of 2p25.3
ranging in size from 0.37 Mb to 3.11 Mb, detected by
genome-wide array analysis, led to the definition of the
smallest region of overlap (SRO) for pure 2p25.3 deletions
in patients with intellectual disabilities (ID) [6] and early-
onset obesity [5]. This region harbours the myelin tran-
scription factor 1-like gene (MYT1L, OMIM: 613084),
coding for a neural transcription factor with a pivotal role* Correspondence: clara.bonaglia@bp.lnf.it
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gene for ID in patients with pure 2p25.3 deletion [6] and
early-onset obesity [5].
Here we report a new patient with moderate intellec-
tual disability (ID), early-onset obesity, and hyperkinetic
syndrome associated to a 2p25.3 simple de novo terminal
deletion of 1.9 Mb disrupting MYT1L.
The causative role of MYT1L haploinsufficiency in
2p25.3 deletion and the involvement of 2pter monosomy
in the chromosomal aetiology for syndromic obesity are
discussed.Case presentation
Informed consent was obtained from both parents of the
patient.
Frontal and lateral view of the patient as well as
growth curves are shown in Figure 1.
The patient came to our attention at the age of 3 years
for intellectual disabilities, obesity, macrosomy, andl Ltd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Details of growth - BMI-for age and facial/physical appearance of the patient. A. On the left, growth curves for our patient
showing early-onset obesity; on the right, BMI at 41 and 53 months. The source of growth and BMI-for-age graphic is: http://www.chartsgraphs
diagrams.com/HealthCharts/growth-2-20-girls.html. B. Photographs of the patient: (a) frontal face, (b) lateral face, and (c) full frontal views. Note
the square-shaped truncal build.
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female, the only child of healthy non-consanguineous
39-year-old mother and 39-year-old father with unre-
markable family history. The father and mother were of
normal height and weight. She was born at 41 weeks of
gestation by caesarean section, due to spontaneous am-
niotic sac rupture without uterine contractions. Birth pa-
rameters were in range (weight: 3090 gr, length: 50.5 cm,
cranial circumference-OFC: 32 cm). Apgar scores were9/10 at 1′/5′, respectively. The perinatal period was un-
remarkable with good neonatal adaptation to extra uter-
ine environment and breast feeding; neither hypotonia
nor jaundice were present. Her psychomotor develop-
ment was characterised by sitting unsupported at
15 months, walking autonomously at 18 months, and
uttering her first words at 18 months. The child devel-
oped obesity during early infancy, despite normal food-
seeking behaviour (Additional file 1: Table S1.) and on
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was 32 Kg (BMI = 23.59) (Figure 1A), length 128 cm
(> > 97thc), OFC 51 cm (50-75thc). At the age of 3 years,
she showed mild to moderate intellectual disabilities
(Leiter-R scale IQ = 79) with main deficit in the verbal
area, both in language comprehension and production.
She was able to produce less than 10 words and unable
to construct even the simplest sentences. The Vineland
Adaptive Behaviour Scale (VABS) was completed by
interviewing both parents. Patient’s age equivalent (AE)
was less than 1 year 9 months; receptive language and
expressive skills score was 1 year 7 months; socialization
AE was less than 1 year 11 months; daily living skills
AE was 2 years 2 months; motor skills AE was 2 years
9 months.
Asynergistic walking with sole-sole pattern with feet
intra-rotation due to intra-rotation of the tibia bilaterally
and anteroversion of the femurs’ neck has been observed.
At ocular evaluation, bilateral amblyopia (4/10) with
mixed astigmatism was observed. Audiometric examin-
ation and brain-stem auditory evoked potentials re-
sulted within normal range, with the exception of a
mild delay of the 1st wave in the right ear due to mild
transmission deficits.
Electroencephalograms (EEG) recording data, acquired
during wake and spontaneous sleep, revealed epileptic
anomalies only during profound sleep.
At last evaluation, at the age of 4 y and 4 mo, her
growth parameters were: weight 39 kg (> > 97thc), length
128 cm (> > 97thc), OFC 51 cm (50-75thc), BMI 24.18
(Figure 1A). Facial examination showed slightly upturned
nose and short neck without other remarkable dimor-
phisms (Figure 1B). Her behaviour was mainly charac-
terised by a severe form of hyperkinetic disorder. Her
attention dwelt no more than a few minutes on a single
information or activity, even when she was extremely
interested and highly focused on it by the examiner’s
intervention. Her spontaneous play activities are basic-
ally unstructured: she holds toys, explores them rapidly
and superficially, then beats them. She appreciates
sensory-motor experiences in play. She has no play
strategies. Spontaneous interaction with relatives, other
adults, and peers is poor but present. At first glance, she
appears to be an autistic girl. However, when faced by
the examiner and stimulated by being presented toys,
she spontaneously tries to share her activities and eye
contact is present. She attends kindergarten for nor-
mally developing children; however, she has a support
teacher for the whole period of her school attendance.
She also has a special teaching schedule and program.
At present, her cognitive functioning is equivalent to
moderate mental retardation with hyperkinetic syndrome.
At last evaluation EEG, compared with the previous
registration, is remarkably better due to a significantreduction of non-convulsive paroxysmal activity during
profound sleep.
Brain MRI showed increased subdural peri-encephalic
space in the frontal regions, and enlarged cisterna magna
without signs of compression on the 4th ventricle or the
cerebellar vermis. No other remarkable signs were evi-
dent. At abdominal echography, no pathological signs
concerning spleen, liver, gallbladder, pancreas, kidneys,
or bladder were observed.
Electrocardiogram (ECG) showed regular sinusoidal
rhythm with 106 bites per minute, conduction and repo-
larization within normal limits, QT tract corrected
385 msec, and arterial hypertension; no pathological
signs were evident at heart echography.
Routine haematological exams revealed increased levels
of platelets (420,000 – normal range 150,000-400,000)
increased triglycerides (217 mg/dL – normal range
40–150) with normal total cholesterol (143 mg/dl- normal
range 120–140). Thyroid function was normal (TSH:
1.198 μUI/ml (N:0.350-5000), T4:13.4 pg/ml (N:8.9-17.6),
and T3: 4.8 pg/ml (N:2.3-4.2)).
Array-CGH analysis, performed with an Agilent Human
Genome CGH Microarray Kit 180 k (Agilent Technologies
Inc., Santa Clara, CA) with a resolution of ~40 Kb re-
vealed a deletion of 1.9 Mb in chromosomal band
2p25.3 (Figure 2A) including the following genes :
FAM110C (OMIM *611395) ACP1 (OMIM *171500),
TMEM18 (OMIM *613200), SNTG2 (OMIM *608715),
TPO (OMIM *608715), MYT1L (OMIM *613084) PXDN
(OMIM *605158) and SH3YL1, FAM150B (Figure 2B). All
nucleotide positions refer to the Human Genome, Feb
2009 Assembly (hg19). Data analysis was performed using
Agilent Cytogenomics version 2.5.8.1. The deletion break-
point, located between 1,957,657 Mb and 1,973,115 Mb
(hg19), lies within intron 6 ofMYT1L.
Real-time quantitative PCR (qPCR) assays, performed
on the patient and her parents using SYBR Green and
analysed on an ABI PRISM 7900HT sequence detection
system (Applied Biosystems, Foster City, CA), demon-
strated that the 2p25.3 deletion originated de novo (data
not shown).
Genotyping of polymorphic locus D2S2268 in the pro-
band and her parents, performed by amplification with
primers labelled with fluorescent probes (ABI 6-Fam and
8-Hex) followed by analysis on ABI 3500AV Genetic
Analyser (Applied Biosystems), revealed the paternal
origin of the deletion (data not shown). The final inter-
pretation of the rearrangement was arr[hg19] 2p25.3
(30,341-1,957,657x1,1,973,115x2) dn.
Including the present case, about 18 patients, with
ages ranging from infancy to adulthood and partially
overlapping 2p25.3 deletions, have been described so
far [5,6]. All these patients share common distinctive
clinical features represented by early-onset obesity/
Figure 2 Molecular details of 2p25.3 deletion. Array- CGH profile of chromosome 2 showing (A) a terminal deletion of 1.9 Mb at 2p25.3, and
(B) an enlargement of the 2p25.3 deletion. Genomic view of the terminal 1.9 Mb of chromosome 2p25.3 (C): UCSC genes (GRCh37/hg19) are
shown. The screenshot shows the deletion breakpoint disrupting MYT1L.
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bles [5,6]. The first symptom observed in our patient
was very early-onset obesity (Figure 1A), starting from
the 3rd month of life (Additional file 1: Table S1). A
square-shaped truncal build was evident (Figure 2B), as
previously reported in four patients out of six by Steven
et al. [6] and two out of five by Doco-Fenzy et al. [5].
Her psychomotor development, resulting in mild to
moderate ID, was mainly characterized by severe lan-
guage delay (less than 10 words) and inability to produce
sentences, even the simplest ones.
By combining genotype-phenotype analysis from all
hitherto reported patients and DECIPHER cases, MYT1L
has recently been proposed as the major candidate gene
for ID [6] and early-onset obesity [5], since the gene is de-
leted in all patients with terminal or interstitial monosomy
of 2p25.3 [5,6]. The causative role of MYT1L haploinsuffi-
ciency for early-onset obesity is further reinforced by our
finding, showing that our patient’s proximal deletion
breakpoint lies within a segment of 15,459 bp located in
the sixth intron of MYT1L (Figure 2C). A very similar
2p25.3 deletion of 1.975 Mb with its deletion breakpoint
within intron 5 of MYT1L has been recently reported
in another patient (PZ1 from [5]) with clinical features
overlapping those of our patient, apart from neonatalhypotonia and failure to thrive. As hypothesized by Doco-
Fenzy et al. [5], ACP1 and TEM18M, usually deleted in
the majority of patients with obesity or overweight, may
concur to the early-onset obesity/overweight observed in
patients with 2pter deletions. We may thus hypothesise
that haploinsufficiency of ACP1, a gene associated with
severe obesity and increased total cholesterol and triglyc-
erides levels [9,10], may also be responsible for the in-
creased levels of triglycerides and obesity observed in our
patient.
Patients with small interstitial deletion involving
MYT1L (P5, SP6 and ID25513 from [5]) manifest behav-
ioural troubles, including autistic spectrum disorders
(ASD) while subjects with 2p25.3 terminal deletions
additionally involving SNTG2 (P1-2,P4 , SP5-6 from [5])
manifest aggressiveness and outbursts [5,6,11].
Our patient carrying a 2p25.3 deletion spanning nine
genes, including SNTG2 and MYT1L (Figure 2B) mani-
fests neither ASD nor aggressiveness and outburst. Her
spontaneous interaction with relatives, other adults, and
peers is poor but present and, if stimulated, she spontan-
eously tries to share her play activities. Her behaviour is
mainly characterised by a severe form of hyperkinetic dis-
order. Overall, hyperactivity appears to be the main behav-
ioural trait observed in patients with 2p25.3 monosomy.
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In conclusion, we identified a de novo 1.9 Mb deletion of
2p25.3 in a girl with distinctive phenotype characterised
by early-onset obesity, ID, and hyperkinetic disorder.
The deletion breakpoint disrupting the MYT1L gene re-
inforces the hypothesis of its primary causative role in
ID, hyperactivity, and obesity.
MYT1L is disrupted or entirely deleted in all hitherto re-
ported patients with subtelomeric 2pter microdeletions.
Combined functional effects of additional multiple
haploinsufficient genes, usually deleted in patients with
2p25.3 monosomy, may concur to cause the observed
clinical signs. Our data further reinforce the notion that
subtelomeric 2p25.3 deletion (size < 3 Mb) results in
syndromic obesity.
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